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Abstract
Background Diabetic retinopathy (DR) is the leading cause of blindness among working-age adults worldwide. Early detec-
tion and treatment are necessary to forestall vision loss from DR.
Methods A working group of ophthalmic and diabetes experts was established to develop a consensus on the key principles 
of an effective DR screening program. Recommendations are based on analysis of a structured literature review.
Results The recommendations for implementing an effective DR screening program are: (1) Examination methods must be 
suitable for the screening region, and DR classification/grading systems must be systematic and uniformly applied. Two-
field retinal imaging is sufficient for DR screening and is preferable to seven-field imaging, and referable DR should be well 
defined and reliably identifiable by qualified screening staff; (2) in many countries/regions, screening can and should take 
place outside the ophthalmology clinic; (3) screening staff should be accredited and show evidence of ongoing training; (4) 
screening programs should adhere to relevant national quality assurance standards; (5) studies that use uniform definitions 
of risk to determine optimum risk-based screening intervals are required; (6) technology infrastructure should be in place 
to ensure that high-quality images can be stored securely to protect patient information; (7) although screening for diabetic 
macular edema (DME) in conjunction with DR evaluations may have merit, there is currently insufficient evidence to sup-
port implementation of programs solely for DME screening.
Conclusion Use of these recommendations may yield more effective DR screening programs that reduce the risk of vision 
loss worldwide.
Keywords Diabetic retinopathy screening · Telemedicine · Evidence-based recommendations
Introduction
Diabetic retinopathy (DR) is a well-known complication of 
diabetes and the main cause of blindness among working-
age adults [1]. Timely detection and treatment of DR can 
prevent blindness, but many people with this condition are 
not diagnosed early enough to be treated effectively. Peo-
ple with sight-threatening DR (STDR) are often asympto-
matic during the period in which the condition is treatable 
by photocoagulation or intravitreal therapy [2]. Therefore, 
community-wide education and implementation of effective 
programs for DR screening are needed.
Numerous screening programs have been established 
throughout the world; these usually involve assessment and 
grading of the eyes of patients with diabetes, and referral of 
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those with STDR to an ophthalmologist. The principles and 
considerations for screening programs, proposed by Wilson 
and Jungner on behalf of the World Health Organization 
in 1968 [3], have been adopted widely in practice, includ-
ing in the English National Health Service (NHS) Diabetic 
Eye Screening Programme [4]. Since the implementation 
of this program in 2003, diabetic retinopathy/maculopathy 
is no longer the leading cause of blindness in the working 
population in England [4]. The International Council of 
Ophthalmology published the 2017 Guidelines for Diabetic 
Eye Care, which includes a guide to DR screening as well 
as follow-up and management based on different resource 
settings [5]. A successfully implemented screening program 
should benefit patients by increasing awareness of the impor-
tance of regular monitoring and providing a prompt referral 
to an ophthalmologist for screen-positive DR, to ultimately 
reduce the risk of sight loss and preserve patient function 
and quality of life [6–8].
Although established screening programs have reduced 
the risk of sight loss among people with diabetes world-
wide, consensus among experts on effective screening in DR 
is lacking. Therefore, a working group of ophthalmic and 
diabetes experts was established and convened through the 
Vision Academy, a Bayer educational initiative, to propose 
evidence-based recommendations for screening for DR. This 
review will present these recommendations, assess unmet 
needs and identify areas for further investigation.
Methods
Searches
A structured literature search with predetermined search 
terms and inclusion/exclusion criteria was undertaken to 
identify studies worldwide that address the effectiveness 
of DR screening programs and screening tools. An initial 
search of MEDLINE/PubMed was performed on March 8, 
2018, using the following search terms: “diabetic retinopa-
thy” OR “diabetic macular edema” OR DME OR “diabetic 
macular oedema” OR DMO AND “screening program” OR 
screening OR “teleretinal screening” OR telemedicine OR 
teleophthalmology.
After screening study titles for relevance, abstracts were 
read, and studies that involved the following were included: 
(1) patients with diabetes, (2) a sample size of > 200 patients 
and (3) quality or cost-effectiveness of DR screening pro-
grams or telemedicine systems. Only studies published in the 
preceding 10 years (to March 8, 2018) were included, and 
those with the greatest scientific impact (average of ≥ 3 cita-
tions per year) were prioritized. No study exclusions were 
made on the basis of gender, age, disease severity, presence 
of comorbidities, socioeconomic status or geographic 
region.
After screening titles and abstracts, the full text from 
231 articles were examined in detail and 89 articles of inter-
est were identified for the review.
Results
Standard imaging techniques
As the pathology of DR includes characteristic microvas-
cular lesions detectable on fundus examination, obtaining 
ophthalmic images is the primary method of screening for 
DR. The most typical imaging method used is retinal fundus 
photography (FP), but dilated slit-lamp biomicroscopy may 
be another option. Results can be assessed at the point of 
care or in a telemedicine setting. Imaging is performed by 
trained personnel (e.g., technicians, nurses, family physi-
cians, optometrists or endocrinologists), and results can be 
evaluated manually by certified graders/readers (e.g., oph-
thalmologists, retina specialists or trained technicians) or 
automatically by image analysis algorithms.
Seven-field stereoscopic FP was recognized as the refer-
ence standard for assessing effectiveness of DR screening 
programs in the Early Treatment Diabetic Retinopathy Study 
(ETDRS) [4]. However, in a review of 45 studies, research-
ers noted that the most commonly used imaging method in 
DR screening was two-field fundus imaging [9].
Both mydriatic and non-mydriatic approaches are com-
mon in DR screening programs. Induction of mydriasis may 
improve specificity of DR detection, but involves longer 
examination time and greater patient discomfort. In a study 
of community-based screening for STDR, Baeza et  al. 
(2009) determined that imaging one non-stereoscopic field 
with a non-mydriatic camera (NMC) was comparable in sen-
sitivity and specificity to seven-field standard stereoscopic 
imaging, as long as mydriasis was performed. If NMC 
screening without mydriasis was performed, the percentage 
of patients referred to ophthalmologists increased from 5 
to 15% because of ungradable photographs [10]. In a meta-
analysis including data published up to June 2009, variations 
in mydriatic status did not significantly affect sensitivity or 
specificity of DR detection [11]. However, subsequent meta-
analyses do not support this. The authors in India concluded 
that non-mydriatic digital imaging had low sensitivity and 
resulted in a high rate of ungradable images, particularly in 
a dark iris population [12]. Similar results were obtained 
in a pilot telescreening study in Italy that involved 22,466 
patients [13]. In a meta-analysis of digital imaging-based 
telemedicine for DR screening, the researchers found that 
diagnostic accuracy was higher when images were obtained 
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when mydriasis was performed versus when it was not, espe-
cially when a wide angle was used [14].
Alternative imaging techniques
Non-mydriatic ultra-wide-field (UWF) imaging and optical 
coherence tomography (OCT) may be applicable in future 
DR screening efforts; work is ongoing to establish the valid-
ity and cost-effectiveness of these tools at the point of care 
and in a telemedicine setting [15–19].
UWF applies the principles of scanning laser ophthal-
moscopy (SLO) with an ellipsoid mirror to capture a 200° 
image versus the 45°–50° image obtained with standard FP. 
This permits imaging of the peripheral retina and observa-
tion of DR lesions that might otherwise be missed [16]. An 
example of an image obtained using UWF FP is shown in 
Fig. 1. A telemedicine program in which trained non-phy-
sicians performed UWF SLO imaging and immediate grad-
ing of minimal DR was found to have good sensitivity and 
specificity [18]. Compared with the reading center evalua-
tion, real-time image evaluation had sensitivity of 0.95 (95% 
confidence interval [CI] 0.94–0.97) and specificity of 0.84 
(95% CI 0.82–0.85) for minimal DR, and for referable DR 
(RDR) had sensitivity of 0.99 (95% CI 0.97–1.00) and speci-
ficity of 0.76 (95% CI 0.75–0.78) [18]. In addition, there 
were relatively few ungradable images (ungradable rate of 
5.3% per eye) [18].
In large-scale DR teleophthalmology programs, results 
from non-mydriatic UWF SLO imaging were found to 
be superior to results from non-mydriatic multifield FP 
[17]. Specifically, UWF imaging reduced the number of 
ungradable eyes by 81%, increased DR detection twofold 
and enabled detection of predominantly peripheral lesions 
(which are suggestive of severe DR) in almost 10% of 
patients [17]. In a study that compared UWF with clinical 
examination alone, UWF imaging allowed for earlier diag-
nosis of more patients with higher-grade DR [20].
In a private multispecialty hospital in the United Arab 
Emirates, imaging with a UWF fundus camera by nursing 
personnel in the endocrinology department was an effective 
form of telemedicine for DR screening [19]. This method 
ameliorated the burden of screening for DR in the retina 
clinic and improved the rate of early detection of DR [19]. 
Although an early UWF SLO study required more time for 
image analysis, yielded a higher rate of ungradable eyes and 
failed to detect some foveal microaneurysms (MA) compared 
to a digital camera [21], a more recent study demonstrated that 
the peripheral lesions detected through UWF imaging showed 
that the level of DR was more severe in 10% of patients than 
shown by non-mydriatic multifield fundus imaging [17].
The value of OCT in conjunction with FP for DR screen-
ing is currently unclear. Unlike two-dimensional FP, OCT 
provides volume and thickness data with three-dimensional 
visualization of pathological changes related to DME and 
can be used to confirm or rule out DME. In cases where 
DME is confirmed, OCT provides objective quantitative 
data to help guide treatment decisions and management of 
DME. Disadvantages of OCT include equipment costs and 
the need for a highly skilled operator to interpret images and 
determine imaging artifacts [15]. OCT is not advocated in 
primary screening because the price of the OCT equipment 
makes it highly unlikely that it will be cost-effective, given 
that in most screening studies at least 65% of the population 
with diabetes do not have DR. Advocates for the use of OCT 
currently recommend that it is only used to confirm DME 
when there is evidence of diabetic maculopathy from stand-
ard digital color photographs and two-dimensional markers. 
This approach has been shown to be cost-effective [22, 23].
Smartphone-based imaging tools may be useful for DR 
screening programs in which cost and availability of trained 
eye care personnel are barriers to implementation [24, 25]. 
However, no handheld device has been found to have com-
parable sensitivity and specificity to seven-field stereoscopic 
photography in detection of STDR. Rajalakshmi et al. [26] 
compared the “fundus on phone” (FOP) smartphone-based 
retinal camera with seven-field digital retinal photography 
and noted that the modalities yielded the same results for 
92.7% of patients (kappa, 0.90). These authors suggested 
that the FOP camera was effective for screening and diag-
nosis of DR and STDR [26]. However, they noted that all 
patients underwent mydriasis in this study and that the 
image quality of the reference standard was superior to that 
of the FOP system. In this study, the smartphone was fixed 
and the patient’s head was secured by using a slit-lamp chin 
rest. This simple variation may significantly improve results 
Fig. 1  Example of a UWF fundus image showing significant fibrosis 
due to proliferative diabetic retinopathy
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from the use of smartphone technology because it reduces 
any image blurring caused by movement of the operator and/
or the patient. More research is needed in terms of multisite 
trialing, measurement of the impact of smartphone-based 
DR assessment on clinical workflow and determination of 
the effects of this technology on health outcomes of screened 
patients [24].
Functional assessments
At present, visual acuity is the most widely used functional 
measure in routine DR screening. Loss of visual acuity may 
occur at different stages of DR, but visual acuity alone is not 
a reliable measure for predicting DR. For example, in a study 
of 1549 patients with diabetes, the sensitivity and speci-
ficity of using subnormal vision to screen for STDR were 
33.4% and 85.9%, respectively [27], which are well below 
recommended thresholds of 80% and 95%, respectively [28]. 
Measuring visual acuity alone may therefore not be sensitive 
enough to detect early DR so should only be used in con-
junction with imaging methods during screening. However, 
as stereoscopic imaging facilities may not be available in 
all centers, in some circumstances it could be necessary to 
rely only on visual acuity measures for detecting potential 
DR. Other measures (including contrast sensitivity, dark 
adaptation and electrophysiologic parameters) can be help-
ful endpoints in translational research [29]. However, more 
research is warranted to determine whether measures other 
than visual acuity have any utility in DR screening [29].
Grading disease severity
Different scales are used for grading the severity of DR. The 
ETDRS scale has 11 grades, from no disease to advanced 
proliferative DR (PDR) [30]. Although this scale is use-
ful for research purposes, it is more complex than what is 
needed for DR screening programs, where the goal is to 
identify patients for referral and treatment. Accordingly, 
grading systems that have fewer grades and therefore sim-
plify classification have been developed for DR screening. 
Typically, these scales acknowledge the four stages of DR: 
mild non-proliferative DR (NPDR), moderate NPDR, severe 
NPDR and PDR [31]. Examples and definitions of the dif-
ferent grades are shown in Table 1  [5, 32, 33].
In a meta-analysis, Bragge et al. (2011) noted inconsist-
encies among DR classification schemes used as a basis for 
referral [11]. According to the International Clinical DR 
and DME Disease Severity Scales, developed by the Global 
Diabetic Retinopathy Project Task Force on behalf of the 
American Academy of Ophthalmology (AAO) in 2002, any 
level of retinopathy more severe than mild retinopathy may 
warrant examination by an ophthalmologist [32]. This means 
that, according to the AAO definition of mild NPDR, a refer-
ral is needed for anything more than “microaneurysms only” 
(ETDRS level > 20) [32]. However, in the Royal College 
Table 1  Examples of grading scales for DR
AAO American Academy of Ophthalmology, DR diabetic retinopathy, ETDRS Early Treatment Diabetic Retinopathy Study, ICO International 
Council of Ophthalmology, IRMA intraretinal microvascular abnormalities, MA microaneurysms, NPDR non-proliferative diabetic retinopathy, 
PDR proliferative diabetic retinopathy, RCOphth Royal College of Ophthalmologists
ETDRS grading (level) ICO grading AAO grading RCOphth grading
No disease (10) No abnormalities No abnormalities No disease
MA only (20) Mild NPDR
MA only
Mild NPDR
MA only
Low risk
Mild NPDR (35) Moderate NPDR
MA + other signs, excluding those indicating 
severe NPDR
Moderate NPDR
MA + other signs, but none defining severe 
NPDR
–
Moderate NPDR (43) – – High risk
Moderately severe NPDR (47) – – –
Severe NPDR (53A–D) Severe NPDR
>20 intraretinal hemorrhages in all quadrants
Venous beading in two or more quadrants
IRMA in one or more quadrant
Severe NPDR
Intraretinal hemorrhages in all quadrants
Venous beading in two or more quadrants
IRMA in one or more quadrant
–
Very severe NPDR (53E) – – –
Mild PDR (61) PDR
Neovascularization and/or vitreous/prereti-
nal hemorrhage
PDR
Neovascularization and/or vitreous/prereti-
nal hemorrhage
PDR
Moderate PDR (65) – – –
High-risk PDR (71, 75) – – –
Advanced PDR (81, 85) – – –
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of Ophthalmologists (RCOphth) grading system, “low 
risk” equates to the AAO definition of mild NPDR, but 
the RCOphth referral for “high risk” is recommended at a 
more advanced stage (ETDRS level of 43) than the equiva-
lent AAO referral (Table 1) [5, 32, 33]. These observations 
underscore that a universal feature-based classification/grad-
ing system for discerning DR is lacking.
Telemedicine‑based screening
Telemedicine is essentially the ability to locally capture digi-
tal data (including images) and send the files to a central-
ized location for evaluation. Telemedicine systems based on 
digital fundus imaging offer a feasible and efficient means 
to screen patients who are not being reached by screening 
efforts in the specialist’s office [2]. A review of the litera-
ture confirmed that telemedicine has the potential to modify 
patient behaviors, which would contribute to diabetes con-
trol and prevention [34]. Telemedicine screening may take 
place at a diabetes clinic; in the primary care offices of a 
physician, optometrist or pharmacist; at university hospitals; 
or in mobile units.
In a randomized controlled trial, Mansberger et al. [35] 
compared the effectiveness of DR telescreening with an 
NMC versus traditional surveillance by an eye care pro-
vider. The authors determined that patients in the telemedi-
cine group were more likely to undergo DR screening in the 
first year of enrollment [35]. Two years into the study, tel-
emedicine-based screening was offered to all patients [36]. 
The authors’ 5-year findings indicate that telemedicine is an 
effective means of initial DR screening and monitoring for 
DR progression [36]. In a hypothetical cohort of unscreened 
patients with type 2 diabetes, a telemedicine-based DR 
screening model with trained technicians had lower costs 
than a physician-based model and produced similar quality-
adjusted life years (QALYs) from a societal perspective [37].
DR screening with a mobile NMC can be beneficial for 
reaching patients who otherwise would not be included 
in a recommended screening program [38]. Cuadros and 
Bresnick [39] noted that patients tend not to seek annual 
DR screening and suggested incorporating telemedi-
cine screening into primary care practices; these authors 
applied EyePACS, a Web-based means of retinopathy 
grading. Results from an Australian study showed that 
general practice-based DR screening is effective, ena-
bling improved recording of screening outcomes and 
facilitating better follow-up of patients with RDR [40]. 
In a review, Das et al. [41] determined that DR is highly 
suitable for telemedicine because it saves time and mini-
mizes lost income for the patient. DR telescreening can 
also provide cost savings for health systems depending on 
the population being screened (see the “Cost-effectiveness 
of screening” section); for example, a review highlighted 
that remote and underserved areas benefited most, with 
one rural teleophthalmology program resulting in savings 
of $150 per patient over 7 years [42].
Based on a literature review, Surendran and Raman 
[43] concluded that telescreening for DR is cost-effective, 
accurate and reliable, and that digital imaging systems are 
safe and effective alternatives to dilated indirect ophthal-
moscopy coupled with biomicroscopy or stereoscopic FP. 
Different countries have different health service systems in 
place, and financial support for screening programs can be 
difficult to secure. Charitable sources, such as the Queen 
Elizabeth Diamond Jubilee Trust, provide grants to fund 
DR screening programs in less developed nations [44].
Pareja-Ríos et al. [45] reviewed 8 years of experience in 
teleophthalmology screening (Retisalud program; Canary 
Islands) and found that the number of patients screened per 
year increased steadily; the waiting times for image assess-
ment decreased, and the ability of family doctors to correctly 
interpret retinographies improved progressively. In addition, 
the rate of ungradable retinographies decreased—partly 
owing to incorporation of mydriasis—and the percentage 
of images graded as normal increased [45]. Moreover, cases 
of severe NPDR and PDR constituted 14% initially and 3% 
at the end of the study. These findings underscore the fact 
that the full benefits of a DR screening program can take 
several years to develop [45].
Staff accreditation and training
An effective DR screening program should include an 
accreditation system and require staff to demonstrate evi-
dence of ongoing training. In the English NHS Diabetic Eye 
Screening Programme, all screeners and graders must show 
evidence of continuing professional development and take 
monthly external quality assurance tests. An international 
version of the accreditation and tests are also available for 
those working outside the UK [4].
Trained primary care physicians have been found to 
grade retinal photographs with acceptable accuracy when 
compared with ophthalmologists. In a study by Farley et al. 
(2008), the trained clinicians failed to refer 35 (10.2%) of 
the 344 patients that the ophthalmologist believed needed 
referral, which was concluded to be reasonable [46]. Romero 
et al. (2010) found grading concordance in terms of DR, 
DME and macular lesions between family physicians and 
reference ophthalmologists; the authors concluded that 
involving family physicians in DR screening can be effective 
[47]. In a retrospective, cross-sectional study in Singapore, 
trained non-physician graders proved to be a satisfactory and 
cost-effective alternative to family physicians for detecting 
DR [48].
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IT infrastructure
DR screening programs should be supported by a strong 
IT infrastructure that safeguards patient data and effectively 
balances image quality and file size. A typical DR screen-
ing program will require approximately 80,000 images to be 
stored per year. Although file size used to be a significant 
constraint [49], more recently file storage technology has 
improved and all files can be stored on a single server. The 
English NHS Diabetic Eye Screening Programme recom-
mends that images captured are compressed to 1 to 2 MB 
[4].
Automated disease detection
The diagnostic performance of artificial intelligence (AI)-
based software for DR detection has been evaluated in sev-
eral studies (Table 2). Deep learning (DL) is an AI-based 
application whereby convolutional neural networks (CNNs) 
train themselves to interpret images by iterative analysis and 
comparison of the output with a reference standard (i.e., 
diagnosis by human graders). The process is repeated by 
the CNN until the diagnostic output agrees with the refer-
ence standard. DL algorithms have been developed for the 
automated detection of DR lesions from color fundus photo-
graphs—these systems are being implemented in screening 
programs and have the potential to reduce screening costs 
and increase service efficiency in healthcare economies in 
the developed world and to aid delivery of DR screening in 
developing and remote settings [16, 50–54]. Retinal fundus 
imaging with an NMC and automated grading take only 10 
minutes, can be performed at the point of care and may obvi-
ate a separate visit to an ophthalmologist [55]. Automated 
analysis of OCT images through use of DL is being explored 
in a collaborative project between Moorfields Eye Hospital 
and Google DeepMind [56], and in other retinal centers of 
excellence [57].
Fleming et al. (2010) affirmed that including automated 
algorithms to identify RDR lesions in digital fundus images 
is likely to be a cost-effective adjunct to manual grading. By 
adding algorithms for detection of exudates and blot hemor-
rhages to an MA detection algorithm, a significant increase 
in sensitivity of RDR detection was achieved, without there 
being an increase in the manual grading workload [58]. The 
automated software detected 100% of patients with prolif-
erative or referable/observable background retinopathy and 
would reduce workload by 36.3% compared with entirely 
manual grading [59].
Quality assurance
Service quality assurance reduces the probability of error 
and risk and helps professionals and organizations improve 
over time. Methods of quality assurance include post hoc 
evaluations of cost-effectiveness and accuracy of image 
grading [60]. In a South African study that included 261 
ophthalmologists and optometrists, the Scottish Diabetic 
Retinopathy Grading Scheme was chosen because sim-
plicity and clear cutoffs for referrals are vital for public 
sector eye clinics that have a high number of patients and 
limited resources [60]. The participants graded 90 retinal 
photographs as an external test of quality assurance, and 
the findings were: large disparities in grader performance; 
a general lack of specificity among screeners; and a mean 
diagnostic odds ratio of 12.3, which was considered to be at 
the low end of the range for a medium level of performance 
(10.13–22.24). The authors concluded that this test process 
was well accepted by participants, demonstrated safety of 
screening and highlighted areas in which more training is 
needed. The authors of this review were in agreement that 
local screening programs should follow national quality 
assurance standards to ensure a safe and effective service 
[60].
Cost‑effectiveness of screening
Cost-effective DR screening programs have been trialed, 
evaluated and fully implemented in many countries [9, 61]. 
In a retrospective review of data from the US Department 
of Veterans Affairs, Kirkizlar et al. (2013) determined that 
a telemedicine program for DR screening was cost-effective 
only for populations > 3500 and patients < 80 years of age 
[31]. In South Africa, researchers concluded that screening 
patients by mobile non-mydriatic digital fundoscopy in a 
primary care setting was cost-effective when images were 
captured by a trained technician and overseen by an oph-
thalmic nurse and the results were read by a medical officer 
[62]. In a public healthcare setting in Hong Kong, investiga-
tors determined that it was cost-effective to screen patients 
with diabetes for DR and age-related macular degeneration 
in the same session [63]. In a study of cost-effectiveness of 
screening and laser treatment for DR and macular edema in 
Malawi, Vetrini et al. (2018) determined that annual photo-
graphic screening with laser treatment for STDR and mac-
ular edema was cost-effective in terms of QALYs gained, 
given an 80% service utilization rate [64]. The program 
was most likely to be cost-effective when utilization was 
high and young patients (simulated age of 30 years) were 
screened [64].
Telemedicine screening systems have been cost-effective 
for monitoring patients with diabetes in rural and urban set-
tings when compared with in-person screening or no screen-
ing. A retrospective chart analysis in Manitoba, Canada, 
which involved 4676 patients with diabetes, demonstrated 
average savings of Can$1007 (approximately US$800) per 
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teleophthalmology examination [73]. Potential savings 
increased as more patients were examined [73].
Screening intervals
There is some uncertainty about the optimal interval for DR 
screening. Tung et al. (2008) stated that annual screening 
for DR was medically and economically worthwhile in a 
Chinese population of patients with type 2 diabetes [74]. In 
England, combining two consecutive years of screening data 
revealed that annualized rates of progression to STDR were 
only 0.7% and 1.9% for those with no DR at either screening 
or with unilateral DR at the second screening, respectively. 
In contrast, the annualized rate was 11% in those with bilat-
eral DR at both screenings. The authors noted that these esti-
mates of the risk of future development of STDR could be 
used to inform decisions regarding screening frequency [75].
DR screening of a hypothetical cohort in rural southern 
India was shown to be cost-effective from a healthcare pro-
vider perspective at 2-year intervals, but not annually [76]. 
From a societal perspective, telescreening was cost-effective 
only as frequently as every 5 years [76]. Romero-Aroca et al. 
[77] suggested that screening for DR every 2.5 years is cost-
effective, but the screening interval should be adjusted to the 
patient’s personal risk factors. Lund et al. [78] conducted 
individualized risk assessments with the aim of optimizing 
screening intervals. They showed that DR progression could 
be reliably predicted and that most patients have a < 5% risk 
of any DR progression in a given year. The authors noted 
that a screening interval of 20 months could be applied to 
these low-risk patients [78]. Similarly, a retrospective analy-
sis of a screening program in Turin showed that less than 
4% of 4294 patients with no DR at baseline progressed to 
RDR over 2 years, irrespective of other clinical variables, 
and none required immediate treatment by an ophthalmolo-
gist [79].
Scanlon et al. [80] determined that, in the absence of 
personalized risk stratification, it was most likely to be 
cost-effective to screen all patients every 3 years; annual 
screening of all patients was not cost-effective. In the context 
of a personalized screening paradigm for STDR, screening 
low-risk patients every 5 years, medium-risk patients every 
3 years and high-risk patients every 2 years was the most 
cost-effective strategy. The authors noted that although the 
algorithm should be applicable in general, more work is 
needed to validate screening in various populations [80].
Risk factors
DR risk has been found to be significantly associated with 
ethnicity, blood pressure, hemoglobin A1c (HbA1c) levels, 
duration of diabetes and pregnancy [35, 81]. Investigators in 
Portugal determined that the incidence of any DR and RDR Ta
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and the DR progression rate were all related to duration of 
diabetes, age at diagnosis and use of insulin [82]. In a cross-
sectional study of four urban US sites, DR was shown to be 
correlated with duration of diabetes, but not with smoking 
status, health insurance status or knowledge of HbA1c level 
[83]. Risk factors associated with DR in a large screening 
study in Spain included duration of diabetes, HbA1c levels, 
blood pressure and hypertension [84]. DR is also associated 
with the presence of other vascular complications that occur 
with diabetes, and the presence of such complications should 
be considered when evaluating a patient’s risk of the pres-
ence or progression of DR [85].
Barriers to screening
In patients with diabetes, increased time from diagnosis to 
first screening episode correlates with more advanced retin-
opathy [86, 87]. In one study, RDR was detected in 2.3% of 
patients screened within 6 months and in 4.2% of patients 
screened 3 years or more after diagnosis [86]. Therefore, 
screening for DR should be done promptly after diagnosis 
and at regular risk-based intervals thereafter.
Numerous factors are known to affect attendance at DR 
screening [87–91]. In an established mobile retinal screen-
ing service in Scotland, poor attendance at screening was 
not linked to gender or to distance from the event, but was 
associated with younger age, longer duration of diabetes, 
smoking, social deprivation, and poor HbA1c and blood 
pressure control; the highest proportion of non-attenders 
were in urban areas [92]. Findings from seven UK screen-
ing programs demonstrated that patients aged 18–34 years 
were least likely to promptly attend screening after registra-
tion with the screening program, and these patients had a 
higher risk of RDR presence at initial screening [87]. In a 
study of screening uptake among 21,797 patients, uptake 
increased with each age stratum from 67% (age 12–39 years) 
to 88% (age 70–79 years) before declining to 79% in those 
aged ≥ 80 years [91]. Decline in the oldest patients may have 
reflected age-related issues such as limited access to screen-
ing services because of comorbidity or reduced mobility. 
Other factors known to lower uptake include poor aware-
ness of the importance of screening, psychological factors 
(such as guilt due to poor diabetic control and fear of laser 
treatment) and practical barriers to attendance [91]. A UK 
study also confirmed that uptake rates were lower in more 
socioeconomically deprived groups; in contrast, practices 
in the most socioeconomically advantaged regions had the 
highest uptake [93]. Moreover, there was robust disparity 
in uptake among the practices, which may have been due 
to variability in the flexibility and availability of screening 
appointments offered [91].
In a US study of low-income patients and their health-
care providers and staffers, investigators found a striking 
lack of agreement in perceived barriers to screening [90]. 
Providers and staffers felt that transportation, language 
issues, cultural beliefs or myths, denial and fear were key 
barriers to DR screening, whereas patients indicated that 
financial burden and depression were the most common 
barriers [90]. Judah et al. [94] evaluated the effectiveness 
of financially incentivizing screening among patients in 
the NHS Diabetic Eye Screening Programme who had 
not attended an appointment for at least 2 years [94]. 
There was no difference in attendance between the fixed 
incentive and control groups (relative risk, 0.70; 95% 
CI 0.35–1.39), and incentives reduced attendance com-
pared with invitation letters in patients who were regular 
non-attenders. The authors emphasized that future work 
should focus on non-financial means of overcoming bar-
riers to screening encountered by patients [94].
In a DR screening program at a publicly funded clinic 
in Alabama, only 30% of the 949 patients with diabe-
tes adhered to interval recommendations for follow-up 
eye appointments [89]. The authors concluded that these 
programs are unlikely to meet public health goals unless 
adherence is promoted through adequate educational ini-
tiatives [89]. Similarly, findings of the Korean National 
Health and Nutrition Examination Survey indicated that 
only 36.3% of patients with diabetes had been screened 
in the previous year [95]. Patients in rural areas and those 
who were less educated (overall or about diabetes care) 
were found to be screened less often [95]. However, poor 
adherence has been reported in both rural and urban set-
tings [2].
Geographic information system (GIS) mapping is use-
ful for visualizing geographic access and barriers to eye 
care and may help identify underserved areas that would 
benefit from expansion of teleophthalmology screening 
programs [88]. In North Carolina, the authors used data 
on 1787 patients with diabetes who underwent retinal 
screening to develop qualitative GIS maps of patient 
and provider density around five telemedicine sites [88]. 
Results indicated that patient accessibility to healthcare 
professionals can be limited by geography and road net-
works. Primary care clinicians were somewhat uniformly 
distributed, but ophthalmologists were concentrated at 
urban centers. The authors emphasized that telemedi-
cine has great potential for reducing barriers to care by 
connecting physicians with patients in rural, remote and 
underserved areas [88].
Another barrier to implementation of effective screen-
ing is delayed examination by a specialist. In a cross-sec-
tional study in Ireland, 395 of 1542 patients were found 
to have some level of DR, and 11 had proliferative STDR 
[96]. Of these, 3 were given specialist appointments that 
were > 5 months from the original referral date [96].
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Screening for DME
Currently, there is a lack of evidence on screening specifi-
cally for DME; however, detection of DME is important 
because this condition is the leading cause of blindness in 
patients with type 2 diabetes [97]. One study from a DME 
screening program in Hong Kong demonstrated a high false 
positive rate (86.6%) and a low positive predictive value 
(13.4%) for screening of DME with mydriatic FP, if macular 
thickness was used to define the presence of macular edema 
[98]. This is the DME screening method currently applied 
in the UK and Hong Kong. The authors noted that it places 
large financial burdens on the healthcare system and can 
cause unnecessary psychological stress for patients because 
of the high false positive rate [98]. As noted earlier, per-
forming OCT scans only on selected patients with suspected 
DME may reduce false positives and improve screening [22].
Dupas et al. [99] incorporated automated detection of 
DME alongside DR grading in 761 patients and noted sen-
sitivity of 72.7% and specificity of 70.9% for DME risk. 
Prescott et  al. [100] applied OCT alongside automated 
grading of fundus photographs to identify DME in 3170 
patients who had positive results for DR in a prior screen 
involving conventional digital photography. This strategy 
yielded cost savings in both England and Scotland [100]. 
Olson et al. [101] considered the cost-effectiveness of add-
ing OCT to a standard digital retinal photograph to detect 
macular edema and found that automated detection of pat-
terns of photographic surrogate markers was superior to 
manual grading for detecting macular edema by OCT. The 
authors also determined that, by incorporating OCT into 
the screen prior to referral, costs could be lowered without 
any additional cases of macular edema being missed. They 
noted that worse visual acuity was associated with a five-
fold higher prevalence of macular edema and therefore sug-
gested including a functional analysis with the automated 
strategy [101].
Summary: Fundamental principles 
of an effective DR screening program
The point of care, imaging methods, use of mydriasis, train-
ing of personnel and cost-effectiveness are important fac-
tors to consider when implementing DR screening programs. 
Standard retinal FP is used most frequently, but other meth-
ods such as UWF may be preferable, particularly if examina-
tions are to occur without induction of mydriasis [17, 18]. 
Although no handheld device has demonstrated sensitivity 
and specificity comparable to seven-field examinations, 
such devices may be preferable from a telemedicine per-
spective and when barriers to standard screening exist. To 
reduce movement artifacts, both the handheld device and the 
patient’s head should be fixed [24–26].
Potential barriers to screening include age (uptake rates 
are lowest in children and younger adults, and in older 
adults with reduced mobility) [91], geography [95], finan-
cial constraints or socioeconomic status [90, 91, 93] and 
lower education level [95]. DR screening via telemedicine 
is effective [35, 36], can improve screening by reducing 
patient-perceived barriers to care [38, 39, 41], may improve 
follow-up [40] and appears to be cost-effective [37]. For any 
DR screening program to be effective, staff accreditation, 
appropriate IT infrastructure, continuing education and qual-
ity assurance procedures need to be in place and national 
standards should be followed [4, 60]. As part of training and 
quality assurance, a uniform system of grading should be in 
place, including a definition of RDR that is understood and 
identified by image graders [32, 52]. Although it is clear that 
using an estimate of future risk of DR, based on factors such 
as age and duration of diabetes, to determine screening inter-
vals is warranted and likely to improve the cost-effectiveness 
of a screening program, methods for risk stratification still 
require standardization and validation [80].
The value of DR screening is now well established, but 
attempts to develop effective DME screening programs 
have, as yet, failed to achieve similar success [98]. However, 
including DME screening as part of DR evaluation may have 
tangible benefits [101].
Based on these considerations, the Vision Academy 
Working Group identified the following basic features for 
implementing an effective screening program for DR. We 
believe that these recommendations will be helpful to oph-
thalmology and diabetology communities.
• Examination methods must be suitable for the screening 
region, and DR classification/grading systems must be 
systematic and uniformly applied.
• Although there is variability among studies in the 
number of image fields acquired (ranging from one 
to nine), two-field retinal imaging is sufficient for DR 
screening and is preferable to seven-field imaging.
• There should be a definition of DR in place that is 
understood and used by screening staff to reliably 
identify RDR.
• In many countries/regions, screening can and should take 
place outside the ophthalmology clinic. Cost-effective 
telemedicine programs can be performed in a variety of 
alternative settings.
• Screening staff should be accredited and show evidence 
of ongoing training.
• Screening programs should adhere to relevant national 
quality assurance standards.
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• Studies that use uniform definitions of risk to determine 
optimum risk-based screening intervals are required.
• Technology infrastructure should be in place to ensure 
that high-quality images can be stored securely to protect 
patient information.
• Although screening for DME in conjunction with DR 
evaluations may have merit, there is currently insufficient 
evidence to support implementation of programs solely 
for DME screening.
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